Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535920 | 0.96 | OPRL1 (0.43) | AROPRK1HRH1CCR3TLR9 | |
| SCHEMBL5530302 | 0.86 | HRH3 (0.43) | ARHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5525555 | 0.86 | HTR1A (0.39) | ARHRH1HTR1AADRA1DADRA1A | |
| SCHEMBL5529926 | 0.85 | NCF1 (0.44) | AROPRK1HRH1CCR3 | |
| SCHEMBL5524449 | 0.83 | HRH3 (0.47) | ARHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5529940 | 0.82 | AR (0.40) | ARHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5532727 | 0.82 | HRH3 (0.42) | ARHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5527453 | 0.82 | NCF1 (0.41) | AROPRK1TLR9TLR8TLR7 | |
| SCHEMBL8235826 | 0.80 | OPRL1 (0.41) | AROPRK1TLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL23360004 | 0.78 | HTR1A (0.44) | ARHRH1HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071055-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | AR 4698/4885OPRK1 290/4885HRH1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.